Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
OCTOPOD: THEO-260 in high-grade serous or endometrioid ovarian cancer
2024-511236-27-00Phase 2Authorised
- Sponsor
- Theolytics
- Start
- Nov 2025
- Modality
- Small Molecules
- Countries
- 3
01
Overview
Phase 2, open-label trial of theophylline in ovarian cancer, fallopian tube cancer (PFTC) and primary peritoneal cancer (PPC) (2 arms), sponsored by Theolytics. Primary endpoints: Safety and tolerability, Recommended phase II dose evaluation and 1 more. Planned start Nov 2025; status: authorised.
02
Drugs
theophylline
03
Conditions
ovarian cancerfallopian tube cancer (PFTC)primary peritoneal cancer (PPC)
Beyond the preview
Go deeper on 2024-511236-27-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-511236-27-00.